SCHEMBL2299658

SCHEMBL2299658

CC(C)[C@H](NC(=O)c1csc(-c2ccc(NC(=O)Nc3ccccc3Cl)cc2)n1)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.66
CSGALNACT1 Q8TDX6 6/20 0.64
TDP1 Q9NUW8 3/20 0.53
MAPT P10636 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
NPY1R P25929 1/20 0.53
NPY2R P49146 1/20 0.53
ATM Q13315 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
IRAK4 Q9NWZ3 2/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
HPGDS O60760 1/20 0.46
SMO Q99835 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2296603 1.00 DGAT1 (0.66) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2293823 0.91 DGAT1 (0.54) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2293820 0.91 DGAT1 (0.54) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2300136 0.83 DGAT1 (0.70) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2300143 0.83 DGAT1 (0.70) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL1756360 0.83 DGAT1 (0.71) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2300052 0.82 DGAT1 (0.64) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2300059 0.82 DGAT1 (0.64) DGAT1CSGALNACT1TDP1MAPTNPSR1
SCHEMBL2298568 0.82 CSGALNACT1 (0.66) DGAT1CSGALNACT1MAPTRAB9AMEN1
SCHEMBL2298564 0.82 CSGALNACT1 (0.66) DGAT1CSGALNACT1MAPTRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT DGAT1 1/4885CSGALNACT1 455/4885TDP1 2645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.